Schizophrenia patients exhibit deficits in signaling of the M 1 subtype of muscarinic
acetylcholine receptor (mAChR) in the prefrontal cortex (PFC) and also display impaired …

Current antipsychotics are effective in treating the positive symptoms associated with
schizophrenia, but they remain suboptimal in targeting cognitive dysfunction. Recent studies …

Positive allosteric modulators (PAMs) of the M4 muscarinic acetylcholine receptor (mAChR)
represent a novel approach for the treatment of psychotic symptoms associated with …

Background In the central nervous system (CNS), the muscarinic system plays key roles in
learning and memory, as well as in the regulation of many sensory, motor, and autonomic …

Schizophrenia is a severe neuropsychiatric disorder characterized by a diverse range of
symptoms that can have profound impacts on the lives of patients. Currently available …

Muscarinic receptors represent a promising therapeutic target for schizophrenia, but the
mechanisms underlying the antipsychotic efficacy of muscarinic modulators are not well …

Although selective activation of the M 1 muscarinic acetylcholine receptor (mAChR) subtype
has been shown to improve cognitive function in animal models of neuropsychiatric …

Muscarinic receptors have been implicated in the regulation of cognition and psychosis
based on pharmacological evidence from pre-clinical and clinical studies. Muscarinic …

Background Preclinical and some human data suggest allosteric modulation of the
muscarinic M1 receptor (CHRM1) is a promising approach for the treatment of …

Alzheimer's disease (AD) is a profoundly debilitating neurodegenerative disorder
characterized most notably by progressive cognitive decline, but also agitation and …